1. Antisense Oligonucleotides (ASOs): A powerful tool in molecular biology and therapeutics, ASOs enable precise control over gene expression at the RNA level. In Angelman Syndrome, ASOs target the typically silenced paternal copy of the UBE3A gene. By disrupting this silencing mechanism, these therapies aim to restore UBE3A protein production.

2. Gene Therapy: A medical approach that modifies or manipulates genes within an individual’s cells by replacing, editing, or regulating gene activity. In Angelman Syndrome, gene therapies (currently in preclinical studies) are being developed to either deliver a functional copy of the UBE3A gene or permanently un-silence UBE3A on the paternal allele.

3. Small Molecule Drugs: These therapies aim to modulate biological pathways affected by the loss of UBE3A. They work to improve synaptic plasticity, reduce neuronal hyperexcitability, and address other neurobiological challenges common in Angelman Syndrome.

4. Protein Replacement Therapy: This approach focuses on delivering functional UBE3A protein to the brain. While challenges such as crossing the blood-brain barrier remain, advancements in nanoparticle technology are improving the feasibility of this treatment.

5. Symptom-Targeted Therapies: These therapies do not address the root cause of Angelman Syndrome but aim to manage symptoms such as seizures, sleep disturbances, and motor impairments. Interventions include anticonvulsants, neurostimulation devices, and behavioral therapies, all of which play a crucial role in improving quality of life.

Clinical trials are typically conducted in several phases:

• Phase 1: Assesses safety and dosage in a small group of healthy volunteers.

• Phase 2: Expands to a larger group to evaluate efficacy and further assess safety.

• Phase 3: Involves a broader population to confirm effectiveness, monitor side effects, and compare the treatment to standard therapies.

• Phase 4: Conducted after approval, focusing on long-term effects and ongoing safety monitoring.

In some cases, phases may be combined—such as Phase 1/2 or Phase 2/3—particularly in rare disease populations like Angelman Syndrome, where limited resources and participant availability necessitate an accelerated approach.

• Not yet recruiting: The study has not started recruiting participants.

• Recruiting: The study is currently recruiting participants.

• Enrolling by invitation: The study is selecting its participants from a population, or group of people, decided on by the researchers in advance. These studies are not open to everyone who meets the eligibility criteria but only to people in that particular population, who are specifically invited to participate.

• Active, not recruiting: The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.

• Suspended: The study has stopped early but may start again.

• Terminated: The study has stopped early and will not start again. Participants are no longer being examined or treated.

• Completed: The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

• Withdrawn: The study stopped early, before enrolling its first participant.

Definitions sourced from ClinicalTrials.gov.